Collectively, the efficacy of vemurafenib beyond melanoma[34], for example in Erdheim-Chester Disease[18] and our data argue for ongoing exploration of the therapeutic value of BRAF mutations in LCH. This evidence concerns the gene BRAF and Langerhans cell histiocytosis.